Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900441 | 1.00 | GSK3B (0.50) | GSK3BGAAL3MBTL1MAPTCYP2C9 | |
| SCHEMBL6902376 | 0.82 | GSK3B (0.48) | GSK3BL3MBTL1MAPTPOLBNPC1 | |
| SCHEMBL6902380 | 0.82 | GSK3B (0.48) | GSK3BL3MBTL1MAPTPOLBNPC1 | |
| SCHEMBL6900741 | 0.81 | TSHR (0.55) | GSK3BGAAL3MBTL1MAPTCYP2C9 | |
| SCHEMBL6897943 | 0.81 | TSHR (0.55) | GSK3BGAAL3MBTL1MAPTCYP2C9 | |
| SCHEMBL6897949 | 0.81 | TSHR (0.55) | GSK3BGAAL3MBTL1MAPTCYP2C9 | |
| SCHEMBL23782425 | 0.81 | KMO (0.62) | — | |
| SCHEMBL24106434 | 0.80 | CES2 (0.46) | GSK3BGAAL3MBTL1MAPTALDH1A1 | |
| SCHEMBL19984701 | 0.79 | GSK3B (0.55) | GSK3BL3MBTL1MAPTCYP2C9CYP2C19 | |
| SCHEMBL6900410 | 0.78 | HDAC3 (0.53) | GSK3BGAAL3MBTL1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833468-B2 | Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-21 | — | — | US | disclosed |
| US-6642409-B2 | Reacting an imine with a hemiacetal; hydrolysis under acid conditions | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-11-04 | — | — | US | disclosed |
| US-6639100-B2 | Baeyer-Villiger oxidation of an optically active 4,4,4-tri-fluoro-3-hydroxy-1-aryl-1-butanone; purification by precipitation and removing racemic crystals; agriculture; drugs; ferroelectric liquid crystals; chemical intermediates | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-10-28 | — | — | US | disclosed |
| US-20030100767-A1 | Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing | CENTRAL GLASS COMPANY, LIMITED | 2003-05-29 | — | — | US | disclosed |
| US-20030088095-A1 | Reacting an optically active imine with a hemiacetal of a perfluoroalkylaldehyde or a hydrate; hydrolyzing the condensate under an acid condition. | CENTRAL GLASS COMPANY, LIMITED | 2003-05-08 | — | — | US | disclosed |
| US-20020016511-A1 | Reacting an imine with a hemiacetal; hydrolysis under acid conditions | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100767-A1 | Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing | ADH1C, ADH1A, HPD | GSK3B 1305/4885GAA 3520/4885L3MBTL1 3918/4885 |
| US-20030088095-A1 | Reacting an optically active imine with a hemiacetal of a perfluoroalkylaldehyde or a hydrate; hydrolyzing the condensate under an acid condition. | ADH1C, ADH1A, HPD | GSK3B 1044/4885GAA 3535/4885L3MBTL1 3968/4885 |
| US-20020016511-A1 | Reacting an imine with a hemiacetal; hydrolysis under acid conditions | ADH1C, ADH1A, HPD | GSK3B 888/4885GAA 3418/4885L3MBTL1 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.